Specialty and Performance Chemicals

Kaneka Corporation

4118

4205

Kaneka Corporation has agreed to acquire Zeon Corporation's medical device businesses in the gastrointestinal and cardiovascular sectors, operated by Zeon Medical Inc. and River Xemex Co., Ltd. This acquisition will position Kaneka as the third-largest player in the domestic gastrointestinal market, particularly in endoscopic treatment devices. The agreement, signed on November 12, 2025, aims to enhance Kaneka's product portfolio and improve patient quality of life.

Reuters

Zeon Corporation

Kaneka Acquires Zeon’s Gastrointestinal and Cardiovascular Medical Device Businesses

Kaneka Corporation revised consolidated earnings guidance for the fiscal year from April 1, 2025 to March 31, 2026. For the year, the company expects net sales of ¥800,000 million compared to previous guidance of ¥820,000 million, operating income of ¥37,000 million compared to previous guidance of ¥42,000 million, net income attributable to owners of parent of ¥33,000 million compared to previous guidance of ¥33,000 million and net income per share of ¥534.03 compared to previous guidance of ¥524.36.

marketscreener

Kaneka Corporation Revises Consolidated Earnings Guidance for the Fiscal Year from April 1, 2025 to March 31, 2026

Kaneka Corporation has launched its i-ED COIL, a brain aneurysm embolization coil, in Europe as of October, following EC certification in July. The product offers enhanced flexibility for treating irregularly shaped aneurysms and is expected to reduce rupture risks. Since its 2019 launch in Japan, sales have grown steadily. Kaneka aims to expand its medical device business and achieve JPY 300 billion in sales by 2030 in the Health Care Solution Unit.

Kaneka Expands Global Reach with i-ED COIL Launch in Europe

Kaneka Corporation has signed an on-site Power Purchase Agreement (PPA) with Hokkaido Numata Town for the installation of bifacial solar panels and battery storage at Horosin Onsen. The project, set to begin operations in April 2026, aims to support decarbonization and provide stable power for local evacuation centers through a microgrid system. It is backed by the Hokkaido Government’s Subsidy Program for New Energy Facilities.

Kaneka Corporation Signs On-Site PPA Agreement with Hokkaido Numata Town

From July 1, 2025 to September 30, 2025, the company has repurchased 1,236,000 shares, representing 1.97% for ¥5,390.04 million. With this, the company has completed the repurchase of 1,485,000 shares, representing 2.37% for ¥6,350.83 million under the buyback announced on May 14, 2025.

Tranche Update on Kaneka Corporation's Equity Buyback Plan announced on May 14, 2025.

Kaneka Corporation reported a 0.2% increase in net sales to ¥198.682 billion for Q1 2025, but net income fell by 39.4% to ¥4.261 billion. Operating income decreased by 20.6% and ordinary income dropped by 40.5%. The company attributed the sales increase to a strengthening yen, while noting significant declines in profits amid a weak economic recovery in China and ongoing global economic uncertainties. Earnings forecasts were provided, but actual performance may vary due to various factors.

Kaneka Corporation Reports 0.2% Increase in Net Sales; Net Income Down 39.4% for Q1 2025

Tokyo-based company Kaneka Corporation (TOKYO:4118) has recently secured the “Halal Certificate (Certification Number: 355-TSRI/24)” for its functional food ingredient, KANEKA UBIQUINOLTM powder, which is the active form of coenzyme Q10. This certification was obtained after assessment by the Shariah Research Institute of Takushoku University and issued by the Japan Muslim Association, a religious corporation. The certification was granted on May 28. Halal certification ensures that the product meets the standards set for consumption by individuals following Islamic dietary laws.

Unusual Whales

Kaneka's KANEKA UBIQUINOL TM receives Halal certificate from Japan Muslim Association, certification number 355-TSRI/24.

Kaneka Corporation has secured Halal certification for its KANEKA UBIQUINOL™, the active form of coenzyme Q10, to enhance sales in Southeast Asia. The certification, issued by the JAPAN MUSLIM ASSOCIATION, confirms compliance with Shariah law, catering to the growing Muslim population, projected to reach 2.2 billion by 2030. This move aligns with Kaneka's mission of promoting wellness through high-quality products.

Kaneka Corporation Secures Halal Certification for KANEKA UBIQUINOL™ to Boost Sales in Southeast Asia

Kaneka Corporation held its 101st Annual General Meeting of Shareholders on June 27, 2025, where all proposals were approved. Twelve members, including Kimikazu Sugawara, Kazuhiko Fujii, and Shinichiro Kametaka, were elected to the Board. Masafumi Nakahigashi was elected as a substitute Outside Audit & Supervisory Board Member. The meeting concluded successfully with all proposals receiving approval.

Kaneka Corporation Concluded Annual General Meeting

Kaneka Corporation held its 101st Annual General Meeting of Shareholders on June 27, 2025, where three proposals were approved. These included the election of twelve Board members, the election of one substitute Audit & Supervisory Board Member, and the provision of a bonus to Board members, all as originally proposed. The original content was published on June 30, 2025, by Kaneka Corporation.

Kaneka Corporation Concluded 101st Annual General Meeting of Shareholders

Kaneka Corporation reported a 5.9% increase in net sales to ¥807.2 billion and a 9.0% rise in net income to ¥25.309 billion for FY2025. Operating income rose by 22.9% to ¥40.05 billion. The company announced an annual dividend of ¥130 per share, with an interim dividend of ¥60 and a year-end dividend of ¥70. Strong performance was noted in Leading-edge Businesses, particularly in Medical and E & I Technology sectors, despite concerns over future visibility due to a sluggish global economy.

Kaneka Corporation Reports 5.9% Increase in Net Sales and 9.0% Rise in Net Income for FY2025; Annual Dividend Set at ¥130 per Share

Kaneka Corporation (TSE:4118) has seen a 38% share price increase over five years, underperforming the market average. Despite a solid EPS growth of 11% annually, the stock price has only risen 7% per year, reflecting cautious market sentiment. The total shareholder return (TSR) over five years was 60%, largely due to dividends. In the past year, shareholders experienced a 1.5% loss, but long-term investors gained 10% annually. Current market conditions may present a buying opportunity, although one warning sign has been identified.

Simplywall

Kaneka's (TSE:4118) five-year earnings growth trails the respectable shareholder returns

Kaneka Corporation reported increased sales and profits for the fiscal year ending March 31, 2025, with total sales reaching ¥807.2 billion, up from ¥762.3 billion the previous year. Net income rose to ¥25.3 billion, and earnings per share climbed to ¥400.91. Despite economic uncertainties, including stagnation in China and market volatility in Europe and the U.S., the company continues to grow, benefiting from a weaker yen for exports. The Japanese economy faces challenges, but Kaneka aims to sustain its growth in the upcoming fiscal year.

Kaneka Corporation Reports Increased Sales and Profits; Net Income Rises with EPS Climbing to ¥400.91

Kaneka Corporation (TSE:4118) has a low P/E ratio of 8x compared to the market average of 13x, raising questions about its earnings outlook. Despite a 60% gain in the last year, analysts predict a 4.8% decline in EPS for the coming year, contrasting with a market growth expectation of 9.8%. This inconsistent earnings growth contributes to its low P/E, suggesting limited potential for share price increases in the near future. Additionally, there is one warning sign for the company that investors should consider.